Alceus Bio

Programming

A close-up of an orange sphere, resembling a tumor cell, enveloped by a white, textured immune cell.

cells

A close-up of an orange sphere, resembling a tumor cell, enveloped by a white, textured immune cell.

to disrupt the root drivers of cancer

Moving beyond T cell biology towards a new class 
of synthetic T cell therapies for solid cancers

Alceus Bio
What we do

We are pioneering a new class of cell therapies by providing T cells with tools that transcend natural evolution.

The problem

Evolution has not provided T cells with the right tools to overcome solid cancers

As a result, CAR T cells have poor persistence and remain susceptible to mechanisms of tumour resistance, including immunosuppression, antigen loss and metabolic hostility.

Nature,

A 3D illustration of a white blood cell with a bright orange nucleus, showcasing cellular structure and organic textures.

reimagined.

Microscopic view of a cell surrounded by a textured, irregular white membrane, featuring a prominent, bright orange nucleus.

The solution

We are readapting CAR T cells to face the unique challenges of solid tumours 
through proprietary synthetic biology platforms.

01

Safely extending the functional persistence of CAR T cells for more effective long-term responses

02

Targeting cancer resistance mechanisms and reprogramming the tumour microenvironment via synthetic payloads

A minimalist illustration depicting a circular structure with various abstract shapes and dots, representing cellular or biological elements.Diagram illustrating CAR T cells inside a cell, highlighting mechanisms to enhance their long-term effectiveness in immunotherapy.Illustration of a cell targeting cancer resistance and reprogramming the tumor microenvironment with synthetic payloads.

The Alceans

Co-Founders

Alexander Evans

Alexander Evans

CEO and Co-Founder
ArrowArrow
Alceus BioLinkedIn
Close

Alexander Evans

CEO and Co-Founder

Alex co-founded Alceus Bio with the mission to create safe and effective cell therapies that can cure solid cancers. He co-developed the foundational IP behind Alceus at the University of Cambridge and is an expert in T cell biology and gene regulation which has been recognised through several awards and high-impact publications.
At Alceus, Alex leads the strategic vision to realise the full potential of T cell therapies for treating solid cancers. Previously, Alex has experience in early-stage biotech venture and supporting founders to realise the real-world impacts of their research.

Alceus BioLinkedIn
Alberto Conti

Alberto Conti

CSO and Co-Founder
ArrowArrow
Alceus BioLinkedIn
Close

Alberto Conti

CSO and Co-Founder

As Chief Scientific Officer at Alceus Bio, Alberto leads the design and development of T cell therapies engineered to overcome the unique challenges faced in solid cancers. Alberto’s focus lies at the intersection of synthetic immunology and tumour biology, where he aims to pioneer the next generation of cell therapies.
His work in Rahul Roychoudhuri’s lab at the University of Cambridge laid the foundations for the technology behind Alceus Bio and has been recognised through multiple awards, patents and publications in high-impact journals.

Alceus BioLinkedIn
Rahul Roychoudhuri

Rahul Roychoudhuri

Academic Co-Founder, CTO
ArrowArrow
Alceus BioLinkedIn
Close

Rahul Roychoudhuri

Academic Co-Founder, CTO

Rahul co-founded Alceus with the mission to develop curative cell therapies for solid cancers using synthetic biology. As Chief Technical Officer, he brings internationally leading expertise in gene regulation, T cell biology and cancer immunotherapy gained through a decades long career, training with Nicholas Restifo and Steven Rosenberg at the US National Cancer Institute, before establishing an independent academic laboratory at the University of Cambridge, where he is Professor of Cancer Immunology and Immunotherapy.
His groundbreaking work on immune regulation and tumour immunosuppression has been recognised through multiple awards and has led to over 60 publications which have been cited 8,800 times.

‍

Alceus BioLinkedIn

Become an  Alcean

Careers
careers@alceus.bio
ArrowArrow
Backed by
Cancer Research Horizons